India, Feb. 8 -- Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with central, branch, and hemiretinal vein occlusions. The data from this trial will support a supplemental Biologics License Application submission to the U.S. Food and Drug Administration in the first quarter of 2025.
The QUASAR trial met its primary endpoint at 36 weeks, with both groups of EYLEA HD patients dosed every 8 weeks achieving non-inferior visual acuity gains compared to those receiving EYLEA (aflibercept) Injection 2 mg dosed every 4 weeks.
The EYLEA HD r...